CANCER TREATMENT _CHEMOTHERAPY_ALTERNATIVES

Pembrolizumab is currently PBS listed for use in classical Hodgkin’s lymphoma, metastatic melanoma and non-small cell lung cancer. The submission requested PBS listing on the basis of a cost-utility analysis comparing pembrolizumab with standard of care (SOC). The key components of the submission are summarised in Table 1. ................
................